Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Discovery | 2 | 2022 | 1057 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 5522 | 0.300 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2007 | 144 | 0.280 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1927 | 0.280 |
Why?
|
| Breast | 1 | 2014 | 1958 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 2906 | 0.240 |
Why?
|
| Mammography | 1 | 2014 | 2474 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 13655 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2023 | 5163 | 0.210 |
Why?
|
| Lead | 1 | 2007 | 854 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 191 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 112 | 0.180 |
Why?
|
| Proteomics | 2 | 2023 | 3618 | 0.180 |
Why?
|
| Epidermal Growth Factor | 1 | 2022 | 709 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2023 | 360 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 2 | 2022 | 944 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2019 | 1970 | 0.170 |
Why?
|
| Cataloging | 1 | 2017 | 8 | 0.160 |
Why?
|
| Staining and Labeling | 1 | 2022 | 1099 | 0.160 |
Why?
|
| Azepines | 1 | 2019 | 336 | 0.150 |
Why?
|
| Microscopy | 1 | 2022 | 903 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2019 | 370 | 0.150 |
Why?
|
| Ubiquitin | 1 | 2022 | 849 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 322 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2007 | 2575 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 535 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 670 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 721 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2022 | 2964 | 0.120 |
Why?
|
| Thalidomide | 1 | 2019 | 888 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1145 | 0.120 |
Why?
|
| Systems Biology | 1 | 2017 | 469 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2014 | 320 | 0.110 |
Why?
|
| Relative Biological Effectiveness | 1 | 2014 | 323 | 0.110 |
Why?
|
| Cell Survival | 1 | 2022 | 5872 | 0.110 |
Why?
|
| Pyrroles | 1 | 2019 | 1143 | 0.110 |
Why?
|
| Cell Line | 4 | 2023 | 15994 | 0.100 |
Why?
|
| Indoles | 1 | 2019 | 1834 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 2948 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 2455 | 0.090 |
Why?
|
| RNA | 1 | 2020 | 2747 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 589 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 3444 | 0.080 |
Why?
|
| Neoplasms | 3 | 2022 | 21596 | 0.080 |
Why?
|
| Cadmium Radioisotopes | 1 | 2007 | 2 | 0.080 |
Why?
|
| Germanium | 1 | 2007 | 7 | 0.080 |
Why?
|
| Cyclotrons | 1 | 2007 | 30 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2023 | 4414 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 16665 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 4823 | 0.070 |
Why?
|
| Molecular Structure | 2 | 2020 | 1907 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8425 | 0.060 |
Why?
|
| Lead Poisoning | 1 | 2007 | 304 | 0.060 |
Why?
|
| Tumor Necrosis Factors | 1 | 2023 | 109 | 0.060 |
Why?
|
| STAT Transcription Factors | 1 | 2023 | 182 | 0.050 |
Why?
|
| Thiolester Hydrolases | 1 | 2022 | 86 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2023 | 244 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5462 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 19862 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2023 | 351 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5662 | 0.050 |
Why?
|
| raf Kinases | 1 | 2019 | 122 | 0.040 |
Why?
|
| Caspases | 1 | 2023 | 928 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 449 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2007 | 2466 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2022 | 772 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 849 | 0.040 |
Why?
|
| Humans | 16 | 2023 | 742088 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2022 | 1011 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 731 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 742 | 0.040 |
Why?
|
| Phthalazines | 1 | 2019 | 361 | 0.040 |
Why?
|
| Organoids | 1 | 2023 | 692 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 647 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2021 | 695 | 0.040 |
Why?
|
| Computational Biology | 2 | 2019 | 3518 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 995 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2019 | 542 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 20774 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2022 | 10472 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3293 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 3133 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1655 | 0.030 |
Why?
|
| Gene Library | 1 | 2017 | 1076 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2023 | 3199 | 0.030 |
Why?
|
| National Health Programs | 1 | 2017 | 445 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 780 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 9715 | 0.030 |
Why?
|
| Mammals | 1 | 2019 | 1135 | 0.030 |
Why?
|
| Phenotype | 2 | 2022 | 16331 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2593 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6313 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 4564 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3689 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2007 | 4231 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 824 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3557 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 1670 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14720 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1581 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2020 | 5454 | 0.020 |
Why?
|
| Female | 7 | 2023 | 379592 | 0.020 |
Why?
|
| DNA Damage | 1 | 2019 | 2423 | 0.020 |
Why?
|
| Piperazines | 1 | 2019 | 2488 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2020 | 8436 | 0.020 |
Why?
|
| Mice | 3 | 2021 | 81045 | 0.020 |
Why?
|
| Animals | 4 | 2021 | 168561 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3564 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5692 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4438 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14554 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9410 | 0.010 |
Why?
|
| United States | 2 | 2019 | 69693 | 0.010 |
Why?
|
| Male | 2 | 2020 | 349538 | 0.010 |
Why?
|
Concepts
(115)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_